Reassessing the OX40/OX40L axis in atopic dermatitis after the termination of Rocatinlimab's clinical development

Thomas Bieber1,2,3

  • 1Department of Dermatology and Allergy, Ludwig-Maximilian University of Munich, Munich, Germany.

Abstract

No abstract available in PubMed .

Related Concept Videos